Transplant center directory

The Transplant and Cellular Therapy Program at Thomas Jefferson University Hospital (TJUH) is focused on innovative haploidentical hematopoietic graft engineering research to overcome access disparities and improve patients’ outcomes. The TJUH Cellular Therapy Program offers all FDA approved CAR T therapies and an expanded portfolio of clinical trials such as “off the shelf” allogeneic CAR T, CAR NK and COVID-19 CTLs.

This center has been performing allogeneic transplants since 1995 and has been an NMDP/Be The Match transplant center since November 1998.

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 130 patients.

The actual 1-year survival of these patients is 65.9%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 62.0% and 77.2%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.